Main Article Content
Low and Medium Income Countries- May 2021
We note with concern, potential misinformation regarding treatment options is recommended to patients in India. We suggest the following evidence-based practice for the management of SARS CoV2 infection.
This work is licensed under a Creative Commons Attribution 4.0 International License.
2 The Writing Committee for the REMAP-CAP Investigators, Angus DC, Derde L, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020;324:1317. doi:10.1001/jama.2020.17022
3 Corticosteroids for COVID-19. REMAP-CAP Trial. https://www.remapcap.org/covid19publications/corticosteroid-for-covid-19 (accessed 1 Jun 2021).
4 Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine 2020;48:e440–69. doi:10.1097/CCM.0000000000004363
5 prone_position_in_adult_critical_care_2019.pdf. https://www.ficm.ac.uk/sites/default/files/prone_position_in_adult_critical_care_2019.pdf (accessed 1 Jun 2021).
6 Bamford P, Bentley A, Dean J, et al. ICS Guidance for Prone Positioning of the Conscious COVID Patient 2020. ;:6.
7 INSPIRATION Investigators, Mazloomzadeh S, Khaleghparast S, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021;325:1620. doi:10.1001/jama.2021.4152
8 CAS-ViewAlert. https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103129 (accessed 1 Jun 2021).
9 Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) | The BMJ. https://www.bmj.com/content/371/bmj.m3939 (accessed 1 Jun 2021).
10 Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | medRxiv. https://www.medrxiv.org/content/10.1101/2021.03.09.21252736v1 (accessed 1 Jun 2021).
11 Convalescent Plasma for COVID-19. REMAP-CAP Trial. https://www.remapcap.org/covid19publications/convalescent-plasma-for-covid-19 (accessed 1 Jun 2021).
12 Convalescent plasma is ineffective for covid-19 | The BMJ. https://www.bmj.com/content/371/bmj.m4072 (accessed 1 Jun 2021).
13 Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 | NEJM. https://www.nejm.org/doi/10.1056/NEJMoa2022926 (accessed 1 Jun 2021).
14 azithromycin-recovery-statement-141220_final.pdf. https://www.recoverytrial.net/files/azithromycin-recovery-statement-141220_final.pdf (accessed 1 Jun 2021).
15 Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;:105949. doi:10.1016/j.ijantimicag.2020.105949
16 Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med Published Online First: 18 March 2020. doi:10.1056/NEJMoa2001282
17 Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext (accessed 1 Jun 2021).
18 REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021;384:1491–502. doi:10.1056/NEJMoa2100433
19 Group RC, Horby PW, Pessoa-Amorim G, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021;:2021.02.11.21249258. doi:10.1101/2021.02.11.21249258
20 Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 2020;79:1277–85. doi:10.1136/annrheumdis-2020-218122
21 PINHO AC. EMA advises against use of ivermectin for the prevention or treatment COVID-19 outside randomised clinical trials. European Medicines Agency. 2021.https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials (accessed 1 Jun 2021).
22 WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials (accessed 1 Jun 2021).
23 Chakravorty S. Vaccines against SARS-Cov-2: An Unprecedented Scientific Triumph and a Source of Hope in the Pandemic. phy 2021;6:1–3. doi:10.38192/22.214.171.124
24 The effects of virus variants on COVID-19 vaccines. https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines (accessed 1 May 2021).